



NEWS RELEASE

SPECTRUM DYNAMICS MEDICAL ANNOUNCES COMMERCIALIZATION AND IMMEDIATE SHIPMENTS OF ITS NEW DYNAMIC SPECT PACKAGE

Palo Alto, CA June 12, 2016 – Spectrum Dynamics Medical Inc. today announced the commercial release of its revolutionary Dynamic SPECT acquisition and processing package.

For the first time using a SPECT device, clinicians will have the capability to not only evaluate perfusion and wall motion, but flow and coronary flow reserve. This new optional software package is available for all D-SPECT 9 detector systems. Shipments are expected to begin this month to new and current installed base customers.

“Spectrum Dynamics Medical could not be more excited about the release as it represents a true breakthrough in the world of Single Photon Emission Computed Tomography (SPECT), providing clinicians with new diagnostic information not possible with previous generations of SPECT systems.” said Josh Gurewitz, Vice President, and Sales & Marketing. Spectrum Dynamics introduced the first clinical & commercially available dedicated CZT based Nuclear cardiac CZT Nuclear imaging system right here at the SNM 2008 and so it is with great pride that we bring one of the most significant clinical developments using CZT technology back to the SNMMI 2016 Gurewitz added.”

###

Main Contact

Josh Gurewitz
Vice President of Sales & Marketing
Tel : + 1 650 800 7030
JoshG@spectrum-dynamics.com

About Spectrum Dynamics Medical

Spectrum Dynamics Medical with offices in California and research and development facilities in Caesarea, Israel is a pioneering medical device company focused on personalized molecular imaging and applications. Spectrum Dynamics Medical revolutionized the practice of nuclear cardiology with the D-SPECT[®] and D-SPECT-L[™] SPECT imaging systems that dramatically enhances image quality, improve workflow, allows the ability to reduce radiation exposure by implementing unique ultra-low dose protocols and provides the platform for upcoming advanced imaging protocols.

For more information, please visit www.spectrum-dynamics.com.

About Biosensors International Group, Ltd.

Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, we are a privately held company.

The Group currently operates through three business units (“BU”): the Cardiovascular BU, composed primarily of the BioMatrix[™] family of drug-eluting stents, the BioFreedom[™] polymer-free drug coated stent and stent technologies such as BA9; the Cardiac Diagnostic BU, including Spectrum Dynamics Medical products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate treatment for patients, and the Critical Care Products BU.

The Group has operations worldwide and is headquartered in Singapore.

For more information, please visit www.biosensors.com.